

Substitute for Form PTO 1449

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****Complete if Known**

(use as many sheets as necessary)

Application No.	10/528,877
Filing Date	
First Named Inventor	Chang, Peter R.
Art Unit	1655
Examiner Name	Amy L Clark
Attorney Docket No.	0100024/0532135

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind code ² (if known)			
/ALC/		US- 3,382,475	08-28-1974	Zirlin	
↓		US- 5,122,381	06-16-1992	Nishimura et al.	
		US- 5,145,781	09-08-1992	Suzuki et al.	
/ALC/		US- 5,565,435	10-15-1996	Yoneyama et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind code ⁵ (if known)				
/ALC/		WO 00-026400	05-11-2000	Merck Patent GmbH	p. p 13-15	✓
↓		WO 01-51482	07-19-2001	Biorex Health Ltd.	p. 6, claim 27	
		WO 01-59143	08-16-2001	Merck Patent GmbH	p. 3, 8, 30, claims 1-4	✓
		CN 1160048	09-24-1997	Zhai Guangyu		Ab.
		EP 0 387 042	02-15-1995	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo		
		EP 0 420 376	03-13-1996	"		
		JP 6128142	05-10-1994	Kose Corp.		Ab.
		JP 02073079	03-13-1990	Daicel Chemical		Ab.
		JP 04066096	03-02-1992	San-Ei Kagaku Kogyo		Ab.
↓		JP 04066098	03-02-1992	San-Ei Kagaku Kogyo		Ab.
/ALC/		JP 6014746	01-25-1994	Omiya Yakugyo; Ito Midori		Ab.

EXAMINER SIGNATURE /Amy Clark/ DATE CONSIDERED 08/29/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application No.	10/528,877
Filing Date	
First Named Inventor	Chang, Peter R.
Art Unit	1055
Examiner Name	Amy L Clark
Attorney Docket No.	10872/0527117

/ALC/		JP 6248267	09-06-1994	SII Techno Res Yugen; Nakayama Tsutomu	Ab.
↓		JP 07324037	12-12-1995	Nippon Getsuto	
		JP 9094077	04-08-1997	San Ei Gen FFI Inc.	Ab.
		DE 4107079	09-10-1992	Merck	Ab.
		DE 4339486	05-24-1995	Backhaus	Ab.
		DE 4340438	06-01-1995	Backhaus	Ab.
↓		SU 904709	02-15-1982	Sechnov, I.M. Medical Institute	Ab.
		CN 1160048	09-24-1997	Peopl. Rep. China	Ab.
/ALC/		CN 1217329	05-26-1999	Huo Xingling	Ab.

OTHER REFERENCES – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
/ALC/		GRIFFITH, JR., J. et al., Effect of rutin on increased capillary fragility in man, Proc. Soc. Exptl. Biol. Med., 1944, vol. 55, pp 228-229	
↓		HUMPHREYS, F.R., The occurrence and industrial production of rutin in southeastern Australia, Economic Botany, 1964, vol. 18, 195-253	
		GRIFFITHS, L.A. & BARROW, A., Metabolism of flavonoid compounds in germ-free rats, Biochem. J., 1972, vol. 130, pp 1161-1162	
↓		UYETA, M., et al., Mutagenicity of hydrolysates of tea infusions, Mutation Research, 1981, vol. 88, pp 233-240	
		BASARKAR, P.W. & NATH, N., Cholesterol lowering action of vitamin P-like compounds in rats, Indian Journal of Experimental Biology, Aug. 1981, vol. 19, pp 787-789	
/ALC/		KATO, N., et al., Effects of dietary quercetin on serum lipids, Agric. Biol. Chem., 1983, vol. 47, no. 9, 2119-2120	
		PROGHAZKA, V., Can wild buckwheat be a commercial source, Naše Liečivé Rastliny, 1985, vol. 22, pt. 5, pp 131-133	
/ALC/		MATSUBARA, Y., et al., Structure and Hypotensive Effect of Flavonoid Glycosides in <i>Citrus unshiu</i> peelings, Agric. Biol. chem., 1985, vol. 49, no. 4, pp 909-914	
/ALC/		BORS, W., et al., [36] Flavonoids as antioxidants, Methods in Enzymology, 1990, vol. 186, pp 343-355, Academic Press	

EXAMINER SIGNATURE /Amy Clark/DATE CONSIDERED 08/29/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application No.	10/528,877
Filing Date	
First Named Inventor	Chang, Peter R.
Art Unit	1655
Examiner Name	Amy L Clark
Attorney Docket No.	10872/0527117

/ALC/		HAYASHIBARA BIOCHEMICAL LABORATORIES INC., Water soluble rutin functioning as vitamin P, Japan Report Medical Technology, Feb. 1990, vol. 4, no. 2,	
		HAYASHIBARA BIOCHEMICAL LABORATORIES INC., Water soluble rutin, New Technology and Products, JETRO, Feb. 1990, p. 34	
		IWATA, K., et al., Effects of kangra buckwheat on spontaneously hypertensive rats, 1990, vol. 21, pp 55-61	
		YILDIZOĞLU-ARI, N., et al. Pharmacological effects of rutin, Phytotherapy Research, 1991, vol. 5, no. 1, pp 19-23	
		ABOU-KARAM, M. & SHIER, W., Isolation and characterization of an antiviral flavonoid from <i>Waldsteinia fragarioides</i> , Journal of Natural Products, Oct. 1992, vol. 55, no. 10, pp 1525-1527	
		DESCHNER, E., Dietary quercetin and rutin, inhibitors of experimental colonic neoplasia, Ch. 19, Phenolic Compounds in Food and Their Effects on Health II, 1992, ACS Symposium Series 507, American Chemical Society, Washington, DC	
		LUTTERODT, G.D. & ABU RAIHAN, S.M., Calcium modulation and antinociceptive efficacy of quercetin compounds, Asia Pacific Journal of Pharmacology, 1993, vol. 8, pp 127-131	
		AGULLO, G., et al., Quercetin exerts a preferential cytotoxic effect on active dividing colon carcinoma HT29 and Caco-2 cells, Cancer Letters, 1994, vol. 87, pp 55-63	
		MIDDLETON, JR., E. & KANDASWAMI, C, The impact of plant flavonoids on mammalian biology: implications for immunity, inflammation and cancer, The Flavonoids: Advances in Research Since 1986, Harborne, J.B., ed., 1994, Ch. 15, pp 619-652, Chapman & Hall, London	
		PISHA, E. & PEZZUTO, J., Fruits and vegetables containing compounds that demonstrate pharmacological activity in humans, Economic and Medicinal Plant Research, 1994, vol. 6, pp 189-233, Wagner & Farnsworth, ed., Academic Press, London	
		OOMAH, D & MAZZA, G., Flavonoids and antioxidative activities in buckwheat, J. Agri. Food Chem., 1996, vol. 44, no. 7, pp 1746-1750	
		MANACH, C., Bioavailability, metabolism and physiological impact of 4-oxo-flavonoids, Nutrition Research, 1996, vol. 16, no. 3, pp 517-544	
		FERRY, D., et al., Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for <i>in vivo</i> tyrosine kinase inhibition, Clinical Cancer Research, April 1996, vol. 2, pp 659-668	
↓		AGULLO, G., et al., Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition, Biochemical Pharmacology, 1997, vol. 53, pp 1649-1657	
/ALC/		WATANABE, J., et al., Isolation and identification of α -glucosidase inhibitors from tochu-cha (<i>Eucommia almoides</i>), Biosci. Biotech. Biochem., 1997, vol. 1, no. 1, pp 177-178	

EXAMINER SIGNATURE /Amy Clark/DATE CONSIDERED 08/29/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application No.	10/528,877
Filing Date	
First Named Inventor	Chang, Peter R.
Art Unit	Koss
Examiner Name	Amy L Clark
Attorney Docket No.	10872/0527117

/ALC/	MANACH, C., et al., Quercetin is recovered in human plasma as conjugated derivatives which retain antioxidant properties, FEBS Letters, 1998, vol. 426, pp 331-336	
	MINAMI, M., et al., Quantitative analysis of rutin in buckwheat (<i>Fagopyrum</i> sp.) by high performance liquid chromatography, Journal of the faculty of agriculture, 1998, vol. 34, no. 2, pp 91-95, Shinshu University, Minamiminowa, Nagano, Japan	
	MORAND, C., et al., Plasma metabolites of quercetin and their antioxidant properties, Am J. Physiol., 1998, vol. 275, pp R212-R219	
	NOROOZI, M., et al., Effects of flavonoids and vitamin C on oxidative DNA damage to human lymphocytes ¹³ , Am. J. Clin. Nutr., 1998, vol. 67, pp 1210-1218	
	CRESPY, V., et al., Part of quercetin absorbed in the small intestine is conjugated and further secreted in the intestinal lumen, Am. J. Physiol. 1999, vol. 277, pp G120-G126	
	ASHIDA, H., et al., Flavones and flavonols at dietary levels inhibit a transformation of aryl hydrocarbon receptor induced by dioxin, FEBS Letters, 2000, vol. 476, pp 213-217	
	BORRELLI, F. & IZZO, A., The plant kingdom as a source of anti-ulcer remedies, Phytother. Res., 2000, vol. 14, pp 581-591	
	CALTAGIRONE, S., ET AL., Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential, Int. J. Cancer, 2000, vol. 87, 595-600	
	GEE, J., et al., Intestinal transport of quercetin glycosides in rats involves both deglycosylation and interaction with the hexose transport pathway, J. Nutri., 2000, vol. 130, pp 2765-2771	
	MORAND, C., et al., Quercetin 3-O- β -glucoside is better absorbed than other quercetin forms and is not present in rat plasma, Free Rad. Res., 2000, vol. 33, pp 667-676	
	SKIBOLA, C & SMITH, M., Potential health impacts of excessive flavonoid intake, Free Radical Biology & Medicine, 2000, vol. 29, nos. 3-4, pp 376-383	
	SLOLEY, B., et al., Chemical and pharmacological evaluation of <i>Hypericum perforatum</i> extracts, Acta Pharmacol Sin, Dec. 2000, vol. 21, no. 12, pp 1145-1152	
	WANG, H., The therapeutic potential of flavonoids, Exp. Opin. Invest. Drugs, 2000, vol. 9, no. 9, pp 2103-2119	
	YEŞİLADA, E., et al., Isolation and characterization of free radical scavenging flavonoid glycosides from the flowers of <i>Spartum junceum</i> by activity-guided fractionation, Journal of Ethnopharmacology, 2000, vol. 73, pp 471-478	
↓	ISHIGE, K., et al., Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms, Free Radical Biology & Medicine, 2001, vol. 30, no. 4, pp 433-446	
/ALC/	VALERIO, L.G., et al., Induction of human NAD(P)H:quinone oxidoreductase (NQO1) gene expression by the flavonol quercetin, Toxicology Letters, 2001, vol. 119, pp 49-57	

EXAMINER SIGNATURE /Amy Clark/DATE CONSIDERED 08/29/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.